Literature DB >> 25808237

[Knowledge of guidelines for anticoagulation management of patients with atrial fibrillation].

Marcus Wiemer1, T Kottmann, M Starrach, D Horstkotte, G Nölker.   

Abstract

INTRODUCTION: In Germany, about 1 million people are affected by atrial fibrillation (AF). Morbidity and mortality are high especially due to the risk of thromboembolic events. A valid risk stratification by the CHADS2 criteria is critical regarding the indication for anticoagulation and thus to improve prognosis. To what extent these criteria and guidelines are known and have been implemented among cardiologists and general practitioners in Germany has not been evaluated so far.
METHODS: A total of 558 cardiologists (46.8 %) and general practitioners (52.5 %) were surveyed during the annual meeting of the German Society of Cardiology or in writing in a representative sample of German general practitioners.
RESULTS: Compared to 51.8 % of general practitioners, 87.6 % of cardiologists (p < 0.001) claimed to know the CHADS2 criteria. In the total cohort, CHADS2 criteria were correctly identified as risk factors by 55.6-86.9 %. Cardiologists had significantly better knowledge of these criteria (63.6-91.2 % vs. 55.6-86.9 %, p < 0.001). A previous history of cerebral stroke was known to be a risk factor in almost all physicians in contrast to heart failure (47.3 % of cardiologists vs. 36.0 % of general practitioners, p < 0.001). Physicians who had attended a training course on anticoagulation and atrial fibrillation (n = 380) in the 2 years prior to the survey performed significantly better (p = 0.007) than those without training (n = 173).
CONCLUSION: While the majority of cardiologists knew the CHADS2 criteria and the related guidelines, these criteria were less known in the primary care sector. Nevertheless, even cardiologists do not always apply the guidelines for anticoagulation in AF correctly. Participants of training courses had a significantly better knowledge of these guidelines.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25808237     DOI: 10.1007/s00399-015-0363-9

Source DB:  PubMed          Journal:  Herzschrittmacherther Elektrophysiol        ISSN: 0938-7412


  14 in total

1.  Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation.

Authors:  Robby Nieuwlaat; Alessandro Capucci; A John Camm; S Bertil Olsson; Dietrich Andresen; D Wyn Davies; Stuart Cobbe; Günter Breithardt; Jean-Yves Le Heuzey; Martin H Prins; Samuel Lévy; Harry J G M Crijns
Journal:  Eur Heart J       Date:  2005-10-04       Impact factor: 29.983

2.  Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis.

Authors:  M Berger; P Schweitzer
Journal:  Am J Cardiol       Date:  1998-12-15       Impact factor: 2.778

Review 3.  Why are we failing to implement effective therapies in cardiovascular disease?

Authors:  Robby Nieuwlaat; Jon-David Schwalm; Rasha Khatib; Salim Yusuf
Journal:  Eur Heart J       Date:  2013-02-01       Impact factor: 29.983

4.  Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.

Authors:  B F Gage; A D Waterman; W Shannon; M Boechler; M W Rich; M J Radford
Journal:  JAMA       Date:  2001-06-13       Impact factor: 56.272

5.  Differences among clinical classification schemes for predicting stroke in atrial fibrillation: implications for therapy in daily practice.

Authors:  Pedro Laguna; Alfonso Martín; Carmen Del Arco; Isabel Millán; Pedro Gargantilla
Journal:  Acad Emerg Med       Date:  2005-09       Impact factor: 3.451

6.  Lifetime cost of ischemic stroke in Germany: results and national projections from a population-based stroke registry: the Erlangen Stroke Project.

Authors:  Peter L Kolominsky-Rabas; Peter U Heuschmann; Daniela Marschall; Martin Emmert; Nikoline Baltzer; Bernhard Neundörfer; Oliver Schöffski; Karl J Krobot
Journal:  Stroke       Date:  2006-03-30       Impact factor: 7.914

7.  Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.

Authors:  Willem J M Dewilde; Tom Oirbans; Freek W A Verheugt; Johannes C Kelder; Bart J G L De Smet; Jean-Paul Herrman; Tom Adriaenssens; Mathias Vrolix; Antonius A C M Heestermans; Marije M Vis; Jan G P Tijsen; Arnoud W van 't Hof; Jurriën M ten Berg
Journal:  Lancet       Date:  2013-02-13       Impact factor: 79.321

8.  [Guideline-adequate knowledge in internists and general practitioners about the diagnosis and treatment of arterial hypertension].

Authors:  C A Schneider; J Hagemeister; H Pfaff; G Mager; H W Höpp
Journal:  Z Arztl Fortbild Qualitatssich       Date:  2001-06

9.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

Authors:  A John Camm; Paulus Kirchhof; Gregory Y H Lip; Ulrich Schotten; Irene Savelieva; Sabine Ernst; Isabelle C Van Gelder; Nawwar Al-Attar; Gerhard Hindricks; Bernard Prendergast; Hein Heidbuchel; Ottavio Alfieri; Annalisa Angelini; Dan Atar; Paolo Colonna; Raffaele De Caterina; Johan De Sutter; Andreas Goette; Bulent Gorenek; Magnus Heldal; Stefan H Hohloser; Philippe Kolh; Jean-Yves Le Heuzey; Piotr Ponikowski; Frans H Rutten
Journal:  Eur Heart J       Date:  2010-08-29       Impact factor: 29.983

10.  Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates.

Authors:  W B Kannel; P A Wolf; E J Benjamin; D Levy
Journal:  Am J Cardiol       Date:  1998-10-16       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.